Forus Raises $150M Series C+ Led by Bain Capital Ventures to Automate Drug Authorization

Forus Secures $150M Series C+ to Scale AI-Powered Prescription Drug Network

Forus, a New York-based healthcare technology company formerly known as Tandem, has raised $150 million in Series C+ funding. The round was led by Bain Capital Ventures, with participation from Thrive Capital, BoxGroup, General Catalyst, Pear VC, Redpoint Ventures, Accel, SV Angel, and Vast Ventures. The funding date is September 8, 2026.

What Forus Does

Forus builds an AI-powered network that automates insurance authorization, financial assistance, and fulfillment routing for prescription drugs. The platform connects providers, pharmacies, payers, and biopharma companies, aiming to streamline the complex process of getting patients access to medications.

Funding Details

• Round type: Series C+
• Amount raised: $150,000,000 USD
• Lead investor: Bain Capital Ventures
• Additional investors: Thrive Capital, BoxGroup, General Catalyst, Pear VC, Redpoint Ventures, Accel, SV Angel, Vast Ventures
• Funding date: September 8, 2026

Why This Matters for Acquirers

The healthcare technology space continues to attract significant capital, particularly for companies addressing administrative inefficiencies in drug access. Forus operates at the intersection of AI, insurance authorization, and pharmaceutical fulfillment—a segment where automation can reduce delays and costs for multiple stakeholders.

With this new funding, Forus is positioned to expand its network and further develop its AI capabilities. The involvement of a broad syndicate including Bain Capital Ventures, Thrive Capital, and General Catalyst signals strong investor confidence in the company's approach to solving authorization and financial assistance challenges.

Acquisition Angle

For companies looking to acquire in the healthcare automation space, Forus represents a potential target with a differentiated network model. Its ability to route prescriptions across providers, pharmacies, payers, and biopharma creates a multi-sided platform that could be attractive to larger healthcare IT vendors, pharmacy benefit managers, or payers seeking to internalize authorization workflows.

The Series C+ round provides Forus with capital to scale operations and potentially increase its market share ahead of any strategic exit. The presence of multiple institutional investors also suggests a well-capitalized cap table, which may influence acquisition dynamics.

Outlook

Forus, formerly Tandem, has now raised a substantial Series C+ round to advance its AI-driven network. As the company deploys this capital, it will be worth watching how it expands its partnerships and whether it can capture a larger share of the prescription drug authorization market. For acquirers, Forus offers a ready-made platform with established investor backing and a clear value proposition in a complex, high-friction area of healthcare.